Hybridoma (Monoclonal Antibody) Core
Hybridoma (Monoclonal Antibody) Core
批准号:
7706296
负责人:
MATTHEW D SCHARFF
金额:
$36.01万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-03-01 至 2009-02-28
关键词:
AffinityAntibodiesAntigensAntitoxinsAntiviral AgentsAscitesAutoimmunityBacillus anthracisBiologicalBioterrorismCancer CenterCellsCloningCommitCommunicable DiseasesCountryDecision MakingDiphtheria ToxinE proteinEnterotoxinsEpidemicFacultyFiberFreezingFundingGenerationsGoalsHumanHuman ResourcesHybridomasImmune SeraImmunityImmunizationImmunoglobulin Somatic HypermutationIn VitroIndividualInstitutionLearningLiquid substanceMalignant NeoplasmsMediatingMedicineMonoclonal AntibodiesMorbidity - disease rateMusNumbersPersonsProcessProductionProductivityPropertyProtein SubunitsProteinsPublic HealthRateRattusResearch PersonnelSCID MiceScreening procedureSerumStaphylococcus aureusTechnologyTestingTetanusTherapeuticTherapeutic antibodiesTimeToxinTrainingUnited StatesViralVirusWest Nile virusWorkactivation-induced cytidine deaminaseanthrax lethal factoranthrax toxincollegeedema factorflasksin vivomembermortalityneutralizing antibodypassive antibodiespressureprophylacticsizetissue culturevirus envelope
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Passive antibody administration is the only strategy available for conferring immediate immunity to
individuals exposed to biological weapons. Furthermore, toxin-specific antibodies are toxin neutralizing
agents par excellence and currently constitute the only means of neutralizing toxins in the human host. The
efficacy of antitoxin sera in human therapy is known since the 1890s when Behring and Kitasato developed
antisera to tetanus and diphtheria toxins and demonstrated their prophylactic and therapeutic properties.
However, despite a century of immunological study we know relatively little about what antibody properties
are important for antitoxin efficacy and the mechanisms involved in toxin neutralization are largely
conjecture. This application is focused on the generation of antibodies to four toxins: B. anthracis toxins
(protective antigen, lethal factor, and edema factor protein subunits) and Staphylococcus aureus enterotoxin
with the goal of generating therapeutic antibodies to protect against biological attack with these agents. In
addition we will generate neutralizing antibodies to West Nile Virus (WNV). The United States is currently in
the midst of an unfolding WNV epidemic and there has been some concern that this agent was deliberately
introduced into this country in an act of bioterrorism. While this is unlikely, the morbidity and mortality
associated with WNV remain a significant public health concern. Four Specific Aims are proposed: 1) To
generate neutralizing (murine and human) mononclonal antibodies to anthrax toxin protein components, S.
aureus enterotroxin, and WNV envelope (E) protein; 2) To identify the antibody attributes necessary for
optimal toxin and viral neutralizing activity; 3) To generate very high affinity derivatives of neutralizing
antitoxin and antiviral mAbs by increasing the rate of somatic hypermutation in selected hybridomas through
expression of activation induced deaminase (AID); 4) To identify the mechanism(s) of antibody-mediated
toxin and virus neutralization.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IMMUNO-ONCOLOGY
-
批准号:7506791
-
项目类别:
-
资助金额:$2.65万
-
财政年份:2007
-
负责人:MATTHEW D SCHARFF
-
依托单位:
PROGRAM LEADERS
-
批准号:7506775
-
项目类别:
-
资助金额:$14.81万
-
财政年份:2007
-
负责人:MATTHEW D SCHARFF
-
依托单位:
Mismatch repair in V region mutation and isotype switching
-
批准号:8403693
-
项目类别:
-
资助金额:$29.6万
-
财政年份:2003
-
负责人:MATTHEW D SCHARFF
-
依托单位:
Mismatch repair in V region mutation and isotype switching
-
批准号:7758277
-
项目类别:
-
资助金额:$32.46万
-
财政年份:2003
-
负责人:MATTHEW D SCHARFF
-
依托单位:
Mismatch Repair in V region mutation and isotype switch
-
批准号:7076248
-
项目类别:
-
资助金额:$32.66万
-
财政年份:2003
-
负责人:MATTHEW D SCHARFF
-
依托单位:
Mismatch repair in V region mutation and isotype switching
-
批准号:9132482
-
项目类别:
-
资助金额:$34.44万
-
财政年份:2003
-
负责人:MATTHEW D SCHARFF
-
依托单位:
Mismatch repair in V region mutation and isotype switching
-
批准号:9109534
-
项目类别:
-
资助金额:$37.58万
-
财政年份:2003
-
负责人:MATTHEW D SCHARFF
-
依托单位:
Mismatch repair in V region mutation and isotype switching
-
批准号:7579404
-
项目类别:
-
资助金额:$32.46万
-
财政年份:2003
-
负责人:MATTHEW D SCHARFF
-
依托单位:
Mismatch Repair in V region mutation and isotype switch
-
批准号:6925507
-
项目类别:
-
资助金额:$33.44万
-
财政年份:2003
-
负责人:MATTHEW D SCHARFF
-
依托单位:
Mismatch repair in V region mutation and isotype switching
-
批准号:8900937
-
项目类别:
-
资助金额:$3.13万
-
财政年份:2003
-
负责人:MATTHEW D SCHARFF
-
依托单位:
Mismatch Repair in V region mutation and isotype switch
-
批准号:6676250
-
项目类别:
-
资助金额:$33.44万
-
财政年份:2003
-
负责人:MATTHEW D SCHARFF
-
依托单位:
Mismatch repair in V region mutation and isotype switching
-
批准号:8001994
-
项目类别:
-
资助金额:$31.49万
-
财政年份:2003
-
负责人:MATTHEW D SCHARFF
-
依托单位:
Mismatch Repair in V region mutation and isotype switch
-
批准号:7222818
-
项目类别:
-
资助金额:$31.71万
-
财政年份:2003
-
负责人:MATTHEW D SCHARFF
-
依托单位:
Mismatch repair in V region mutation and isotype switching
-
批准号:8694686
-
项目类别:
-
资助金额:$37.58万
-
财政年份:2003
-
负责人:MATTHEW D SCHARFF
-
依托单位:
Mismatch Repair in V region mutation and isotype switch
-
批准号:6766016
-
项目类别:
-
资助金额:$33.44万
-
财政年份:2003
-
负责人:MATTHEW D SCHARFF
-
依托单位:
Mismatch repair in V region mutation and isotype switching
-
批准号:8204692
-
项目类别:
-
资助金额:$31.49万
-
财政年份:2003
-
负责人:MATTHEW D SCHARFF
-
依托单位:
The Production of More Effective Monoclonal Antibodies
-
批准号:6562150
-
项目类别:
-
资助金额:$25.05万
-
财政年份:2002
-
负责人:MATTHEW D SCHARFF
-
依托单位:
The Production of More Effective Monoclonal Antibodies
-
批准号:6648347
-
项目类别:
-
资助金额:$25.05万
-
财政年份:2002
-
负责人:MATTHEW D SCHARFF
-
依托单位:
CORE--GLASSWARE WASHING FACILITY
-
批准号:6320792
-
项目类别:
-
资助金额:$28.79万
-
财政年份:2000
-
负责人:MATTHEW D SCHARFF
-
依托单位:
CORE--HYBRIDOMA FACILITY
-
批准号:6320795
-
项目类别:
-
资助金额:$28.79万
-
财政年份:2000
-
负责人:MATTHEW D SCHARFF
-
依托单位:
海外基金